ERIC JONASCH to Clinical Trials as Topic
This is a "connection" page, showing publications ERIC JONASCH has written about Clinical Trials as Topic.
Connection Strength
0.388
-
Targeted therapy for locally advanced renal cell carcinoma. Target Oncol. 2010 Jun; 5(2):113-8.
Score: 0.180
-
Kidney cancer: current and novel treatment options. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):679-81.
Score: 0.063
-
Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J. 2008 Sep-Oct; 14(5):315-9.
Score: 0.040
-
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. J Natl Cancer Inst. 2021 03 01; 113(3):234-243.
Score: 0.023
-
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45.
Score: 0.022
-
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw. 2011 Feb; 9 Suppl 1:S1-29.
Score: 0.012
-
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010 Dec; 58(6):819-28.
Score: 0.011
-
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):618-30.
Score: 0.010
-
Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep. 2008 May; 10(3):253-8.
Score: 0.010
-
Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):1038-58.
Score: 0.009
-
Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):1072-81.
Score: 0.009